• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合 A20 和含三联基序蛋白 44 作为日本人群乳腺癌患者的不良预后因素。

Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population.

机构信息

Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo, Japan.

出版信息

Pathol Int. 2021 Jan;71(1):60-69. doi: 10.1111/pin.13047. Epub 2020 Nov 7.

DOI:10.1111/pin.13047
PMID:33159706
Abstract

We previously reported that a strong immunoreactivity of tripartite motif-containing 44 (TRIM44) predicts the poor prognosis of patients with invasive breast cancer, and proposed that TRIM44 activates nuclear factor-κB (NF-κB) signaling as a causative mechanism. In the present study, we examined the clinicopathological roles of A20, which is known to be an NF-κB responsive gene, with TRIM44, in an updated cohort. Tissue samples of invasive breast cancer were obtained from 140 Japanese female breast cancer patients who underwent surgical treatment. Immunoreactivities of A20 and TRIM44 were analyzed using specific antibodies for each protein. A positive A20 immunoreactivity was significantly associated with a shorter disease-free survival (P = 0.043) and was positively correlated with TRIM44 immunoreactivity (P = 0.039). Combined use of the immunoreactivities for two proteins revealed that double-positive status for both A20 and TRIM44 immunoreactivities was associated with a shorter disease-free survival (P = 0.012) and was an independent factor for poor prognosis. These results indicate that a combined A20 and TRIM44 immunoreactivity predicted the prognosis of patients with invasive breast cancer. Moreover, the positive correlation between A20 and TRIM44 immunoreactivities suggested that the activation of NF-κB signaling by TRIM44 could occur in clinical breast cancer tissues.

摘要

我们之前报道过三结构域蛋白 44(TRIM44)的强免疫反应性可预测浸润性乳腺癌患者的不良预后,并提出 TRIM44 作为一种致病机制激活核因子-κB(NF-κB)信号通路。在本研究中,我们在一个更新的队列中,用 TRIM44 检测了已知是 NF-κB 反应基因的 A20 的临床病理作用。从 140 名接受手术治疗的日本女性乳腺癌患者中获得了浸润性乳腺癌的组织样本。使用每种蛋白的特异性抗体分析 A20 和 TRIM44 的免疫反应性。A20 的阳性免疫反应性与无病生存期显著相关(P=0.043),并且与 TRIM44 免疫反应性呈正相关(P=0.039)。两种蛋白免疫反应性的联合使用表明,A20 和 TRIM44 免疫反应性均为双阳性与无病生存期较短相关(P=0.012),是预后不良的独立因素。这些结果表明,A20 和 TRIM44 的联合免疫反应性可预测浸润性乳腺癌患者的预后。此外,A20 和 TRIM44 免疫反应性之间的正相关性表明,TRIM44 可以在临床乳腺癌组织中激活 NF-κB 信号通路。

相似文献

1
Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population.联合 A20 和含三联基序蛋白 44 作为日本人群乳腺癌患者的不良预后因素。
Pathol Int. 2021 Jan;71(1):60-69. doi: 10.1111/pin.13047. Epub 2020 Nov 7.
2
TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.TRIM44作为NF-κB信号通路的调节因子,是乳腺癌患者预后不良的一个因素。
Int J Mol Sci. 2017 Sep 8;18(9):1931. doi: 10.3390/ijms18091931.
3
Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.三结构域蛋白 44 的表达及其在人类恶性肿瘤中的预后和临床病理价值:一项荟萃分析。
BMC Cancer. 2020 Jun 5;20(1):525. doi: 10.1186/s12885-020-07014-w.
4
High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer.TRIM44 高表达可作为宫颈癌诊断和预后的有价值的生物标志物。
Biosci Rep. 2019 Mar 6;39(3). doi: 10.1042/BSR20181639. Print 2019 Mar 29.
5
Correlation between tripartite motif-containing protein 44 protein expression and the prognosis of postoperative patients exhibiting skin squamous cell carcinoma.含三联基序蛋白44的蛋白表达与皮肤鳞状细胞癌术后患者预后的相关性
Medicine (Baltimore). 2018 Nov;97(44):e13021. doi: 10.1097/MD.0000000000013021.
6
Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.联合使用 RIG-I 的免疫反应性与 Efp/TRIM25 预测雌激素受体阳性乳腺癌患者的预后。
Clin Breast Cancer. 2021 Oct;21(5):399-407.e2. doi: 10.1016/j.clbc.2020.12.001. Epub 2020 Dec 9.
7
The Novel Target of Colorectal Carcinoma: TRIM44 Regulates Cell Migration and Invasion via Activation of CXCR4/NF-κB Signaling.结直肠癌的新靶点:TRIM44通过激活CXCR4/NF-κB信号通路调控细胞迁移和侵袭
Cell Biochem Biophys. 2021 Mar;79(1):113-121. doi: 10.1007/s12013-020-00955-w. Epub 2020 Nov 5.
8
Tripartite Motif-Containing 44 is Involved in the Tumorigenesis of Laryngeal Squamous Cell Carcinoma, and its Expression is Downregulated by Nuciferine.含三联基序蛋白44参与喉鳞状细胞癌的肿瘤发生,且其表达受荷叶碱下调。
Tohoku J Exp Med. 2021 May;254(1):17-23. doi: 10.1620/tjem.254.17.
9
Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer.TRIM44的过表达是预测上皮性卵巢癌预后不良的独立标志物。
Exp Ther Med. 2018 Oct;16(4):3034-3040. doi: 10.3892/etm.2018.6541. Epub 2018 Jul 30.
10
Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.胃癌患者 TRIM44 表达的临床意义。
Asian Pac J Cancer Prev. 2022 May 1;23(5):1725-1731. doi: 10.31557/APJCP.2022.23.5.1725.

引用本文的文献

1
Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer.三重基序家族蛋白(TRIMs)在乳腺癌中的新作用。
Cancer Med. 2024 Jul;13(14):e7472. doi: 10.1002/cam4.7472.
2
TRIM44 regulates tumor immunity in gastric cancer through LOXL2-dependent extracellular matrix remodeling.TRIM44通过依赖赖氨酰氧化酶样蛋白2(LOXL2)的细胞外基质重塑来调节胃癌中的肿瘤免疫。
Cell Oncol (Dordr). 2023 Apr;46(2):423-435. doi: 10.1007/s13402-022-00759-5. Epub 2022 Dec 13.
3
Cardiac-specific Trim44 knockout in rat attenuates isoproterenol-induced cardiac remodeling via inhibition of AKT/mTOR pathway.
心脏特异性 Trim44 敲除可通过抑制 AKT/mTOR 通路减轻异丙肾上腺素诱导的心脏重构。
Dis Model Mech. 2023 May 1;16(5). doi: 10.1242/dmm.049444. Epub 2022 Aug 18.
4
YTHDF1 promotes the proliferation, migration, and invasion of prostate cancer cells by regulating TRIM44.YTHDF1 通过调控 TRIM44 促进前列腺癌细胞的增殖、迁移和侵袭。
Genes Genomics. 2021 Dec;43(12):1413-1421. doi: 10.1007/s13258-021-01175-z. Epub 2021 Oct 22.
5
TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer.TRIM47通过稳定PKC-ε/PKD3激活NF-κB信号通路,并促进乳腺癌的内分泌治疗耐药性。
Proc Natl Acad Sci U S A. 2021 Aug 31;118(35). doi: 10.1073/pnas.2100784118.